China's National Development and Reform Commission lowered from more than 2,000 to about 500 the number of drugs considered critical to health and subject to low-price caps. The commission noted that low prices have limited manufacturers' ability to absorb rising costs and caused shortages of some medicines. The commission has not announced the results of its yearlong investigation into the pricing practices of Chinese and international pharmaceutical firms.

Full Story:

Related Summaries